枸橼酸铁水合物治疗中铁蛋白升高与促红细胞生成素反应性改善
该研究基于日本枸橼酸铁水合物III期长期临床试验数据,分析血液透析患者铁蛋白升高的相关因素及其对促红细胞生成素抵抗指数的影响。结果显示枸橼酸铁水合物剂量与铁蛋白变化相关性最强,其次为促红细胞生成素剂量减少;铁蛋白最低分位组促红细胞生成素抵抗指数显著降低。提示铁负荷与促红细胞生成素减量共同参与铁蛋白升高,并可能改善促红细胞生成素反应性。
要点
- 枸橼酸铁水合物剂量是与铁蛋白变化相关性最强的因素。
- 促红细胞生成素剂量减少是铁蛋白升高的第二强相关因素。
- 基线铁蛋白最低分位组促红细胞生成素抵抗指数显著降低。
核心结论
- 枸橼酸铁水合物治疗期间铁蛋白升高不仅与铁负荷有关,还可能涉及促红细胞生成素剂量减少,并伴随促红细胞生成素抵抗指数下降。
研究设计与样本
- 基于日本枸橼酸铁水合物III期长期临床试验数据,分析血液透析患者铁蛋白升高因素及促红细胞生成素抵抗指数变化。
主要发现
- 枸橼酸铁水合物剂量与铁蛋白变化相关性最强,促红细胞生成素剂量减少次之。
- 铁蛋白最低分位组(<Q1)的促红细胞生成素抵抗指数均值降低。
- 铁蛋白最低分位组基线铁蛋白水平显著更低。
临床怎么用
- 监测枸橼酸铁水合物治疗下铁蛋白变化时,应同时关注促红细胞生成素剂量调整对铁蛋白的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In hemodialysis patients on ferric citrate hydrate, the increase in ferritin level is mainly due to the administration of the compound. We investigated possible other factors associated with ferritin level and how erythropoietin resistance index and erythropoiesis in those patients were affected. We looked at ferritin-elevating factors using data from a Japanese phase III long-term clinical trial of ferric citrate hydrate. METHODS: The factors with a strong association with ferritin levels at week 28 were selected by the process of variable selection. In addition, selected factors were analyzed by Mixed Model for Repeated Measurement. Subjects were divided into 3 groups by quantiles (<Q1, Q1-Q3, Q3<) of the most strongly correlated factors. Then the least-squares means of change of ferritin at each time point for each group were calculated. Finally, the differences of the least-squares means were examined. Changes of both erythropoiesis-stimulating agent dose and erythropoietin resistance index for each group were investigated. The differences in mean erythropoietin resistance index between groups at baseline, week 28, and week 52 were analyzed using t tests. RESULTS: Dose of ferric citrate hydrate showed the strongest correlation with change of ferritin and the second strongest was the reduction of erythropoiesis-stimulating agents. The mean erythropoietin resistance index was lowered in group <Q1. Group <Q1 showed significantly lower levels of ferritin at baseline. DISCUSSION: It is suggested that not only iron load but also the erythropoiesis-stimulating agent dose reduction may be involved in ferritin elevation during ferric citrate hydrate treatment, resulting in a decrease of erythropoietin resistance index.
引用
- Yokoyama K, Fukagawa M, Akiba T, et al. Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate. Kidney Int Rep. 2017. PMID: 29142965. doi:10.1016/j.ekir.2016.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。